GLP-1 Drugs Linked to Lower Diabetic Foot Amputation Risk Than SGLT2 Inhibitors
Real-world data shows GLP-1 users had significantly lower odds of foot ulcers, bone infections, and amputations compared to SGLT2 inhibitor users.
Summary
A large real-world study comparing two popular diabetes drug classes found that GLP-1 receptor agonists were associated with meaningfully lower risks of serious diabetic foot complications than SGLT2 inhibitors. Over a five-year follow-up, people taking SGLT2 inhibitors had 30% higher odds of bone infections in the foot, 11% higher odds of foot ulcers, and 24% higher odds of lower-limb amputation compared to GLP-1 users. Interestingly, SGLT2 inhibitors were tied to slightly lower rates of new nerve damage, yet this did not translate into better foot outcomes, highlighting how complex diabetic foot disease really is. For the millions of type 2 diabetes patients on these medications, these findings could meaningfully influence prescribing decisions around limb health.
Detailed Summary
For people managing type 2 diabetes, the choice between GLP-1 receptor agonists and SGLT2 inhibitors has long been guided by cardiovascular and kidney outcomes. A new large-scale real-world analysis presented at ENDO 2026 adds an important dimension: the risk of serious diabetic foot complications differs significantly between these two drug classes.
Analyzing data from the TriNetX database with propensity matching to control for demographics and comorbidities, researchers followed adults with type 2 diabetes over five years. Compared to GLP-1 users, those on SGLT2 inhibitors faced a 30% higher risk of osteomyelitis (bone infection), a 24% higher risk of lower-extremity amputation, and an 11% higher risk of diabetic foot ulcers. All findings were statistically robust with p-values below 0.001.
One counterintuitive finding emerged: SGLT2 inhibitor users had a small but statistically significant reduction in new-onset diabetic peripheral neuropathy. Yet this neuropathy advantage did not protect against worse foot outcomes, underscoring that diabetic foot disease involves multiple overlapping mechanisms beyond nerve damage alone — including blood vessel health, immune response, and wound healing.
The history of SGLT2 inhibitors and amputation risk is complicated. An early signal from the CANVAS canagliflozin trial prompted an FDA boxed warning, which was later removed as cardiovascular and kidney benefits emerged from longer trials. This inconsistency across studies makes class-level conclusions difficult. GLP-1 drugs, by contrast, have consistently shown no amputation safety signal and some evidence of limb protection in prior research.
For clinicians and health-conscious patients, these findings suggest that limb health should be factored into medication selection — especially for those already at elevated risk for diabetic foot disease. However, as a retrospective observational study, causality cannot be confirmed, and individual clinical context remains paramount.
Key Findings
- SGLT2 inhibitor users had 30% higher osteomyelitis risk versus GLP-1 users over 5 years
- Lower-extremity amputation risk was 24% higher in SGLT2 inhibitor users compared to GLP-1 users
- Diabetic foot ulcer risk was 11% higher among SGLT2 inhibitor users than GLP-1 users
- SGLT2 inhibitors were tied to slightly lower neuropathy risk, yet still showed worse foot outcomes
- GLP-1 drugs have shown consistent limb-protective signals across multiple real-world analyses
Methodology
This is a conference news report from MedPage Today covering a presentation at ENDO 2026. The underlying study is a large retrospective real-world analysis using the TriNetX database with propensity score matching; it has not yet been published in a peer-reviewed journal, so full methodology details are pending.
Study Limitations
As a retrospective observational study, confounding cannot be fully eliminated despite propensity matching. The data comes from a conference abstract and has not yet undergone full peer review. Prior amputation risk data for SGLT2 inhibitors has been inconsistent across trials, complicating class-level interpretation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.